Francisco Gayá

Hospital Universitario La Paz

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Enrique J. Gómez Aguilera

Universidad Politécnica de Madrid

Rosário Madero

Hospital Universitario La Paz

Fernando Cabañas

Hospital Universitario Quirónsalud Madrid

Pablo Lamata

King's College London

José Ramón Arribas

Hospital Universitario La Paz

Adelina Pellicer

Hospital Universitario La Paz

Francisco del Pozo

Instituto de Salud Carlos III

Eva Valverde

Hospital Universitario La Paz

Alfredo García‐Alix

Hospital Sant Joan de Déu Barcelona

J Quero

Hospital Universitario Virgen del Rocío

Cooperative Institutions

Hospital Universitario La Paz

104

Centro de Investigación Biomédica en Red

Hospital La Paz Institute for Health Research

Instituto de Salud Carlos III

Universidad Autónoma de Madrid

Universidad Complutense de Madrid

Centre for Biomedical Network Research on Rare Diseases

Research Institute Hospital 12 de Octubre

Universitat de Barcelona

Universitat Autònoma de Barcelona

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Compact laser radar and three-dimensional camera

Journal of the Optical Society of America A (2006)

A. N. Medina Francisco Gayá Francisco del Pozo

A novel three-dimensional (3D) camera is capable of providing high-precision 3D images in real time. The camera uses a diode laser to illuminate the scene, a shuttered solid-state charge-coupled device (CCD) sensor, and a simple phase detection technique based on the sensor shutter. The amplitude of the reflected signal carries the luminance information, while the phase of the signal carries range information. The system output is coded as a video signal. This camera offers significant advantages over existing technology. The precision in range is dependent only on phase shift and laser power and theoretically is far superior to existing time-of-flight laser radar systems. Other advantages are reduced size and simplicity and compact and inexpensive construction. We built a prototype that produced high-resolution images in range the (z) and x-y.

SIGNAL (programming language)

Charge-coupled device

Rolling shutter

Laser diode

10.1364/josaa.23.000800

Cite

Citations (39)

A new method for quantitative evaluation of target volume variations in radiotherapy planning

IFMBE proceedings (2009)

Francisco Gayá B. Rodríguez-Vila Francisco del Pozo F. Garcı́a‐Vicente Enrique J. Gómez Aguilera

10.1007/978-3-540-89208-3_125

Cite

Citations (2)

Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretrovirals

Journal of Antimicrobial Chemotherapy (2010)

Arkaitz Imaz Josep M. Llibre Marta Mora-Rillo Gràcia Mateo Ángela Camacho

The advent of new antiretrovirals has expanded the therapeutic options for multiple drug-resistant HIV-1 infection. The role of recycled nucleoside reverse transcriptase inhibitors (NRTIs) in this scenario remains uncertain.Observational study of 122 consecutive patients with prior triple-class failure and multidrug-resistant HIV infection who started a salvage regimen with at least three of the new antiretrovirals darunavir, etravirine, raltegravir and maraviroc. Virological, immunological and clinical outcomes were compared according to the inclusion or not of NRTIs in the regimen, after 48 weeks of follow-up.All patients received at least two and 65% received three fully active drugs in the salvage regimen. In 63 patients recycled NRTIs were added to new drugs (NRTI-containing group) and 59 patients did not receive NRTIs (NRTI-sparing group). Both groups were comparable at baseline regarding the number of prior failures, resistance profile, CD4 cell count and HIV plasma viral load. The rates of HIV-1 RNA suppression below 50 copies/mL at week 48 (intent-to-treat analysis) were similar in the two groups: 46/59 [78%, 95% confidence interval (CI) 67%-88%] in the NRTI-sparing group and 49/63 (78%, 95% CI 67%-88%) in the NRTI-containing group. No significant differences were found in CD4 cell count increases. Drug-related adverse events leading to drug discontinuations only occurred in the NRTI-containing group (5 of 63, NRTI-related in 3 cases).The addition of NRTIs with reduced activity, according to genotypic resistance tests, does not seem to improve the efficacy of salvage regimens containing three of the new antiretrovirals in patients with multidrug-resistant HIV-1 infection.

Raltegravir

Etravirine

Regimen

Salvage therapy

Maraviroc

Darunavir

Reverse-transcriptase inhibitor

10.1093/jac/dkq432

Cite

Citations (21)

A New Methodology to Characterize Sensory Interaction for Use in Laparoscopic Surgery Simulation

Lecture notes in computer science (2004)

Pablo Lamata Enrique J. Gómez Aguilera Francisco M. Sánchez‐Margallo Félix Lamata Francisco Gayá

Relevance

Sensory cue

Surgical instrument

Invasive surgery

10.1007/978-3-540-25968-8_20

Cite

Citations (0)

Neurocognitive Impairment in Patients Treated with Protease Inhibitor Monotherapy or Triple Drug Antiretroviral Therapy

PLoS ONE (2013)

Ignacio Valero Alicia González-Baeza Miriam Estébanez María Luisa Montes-Ramírez Carmen Bayón

Background In patients who remain virologically suppressed in plasma with triple-drug ART a switch to protease inhibitor monotherapy maintains high rates of suppression; however it is unknown if protease inhibitor monotherapy is associated to a higher rate of neurocognitive impairment. Methods In this observational, cross-sectional study we included patients with plasma virological suppression (≥1 year) without concomitant major neurocognitive confounders, currently receiving for ≥1 year boosted lopinavir or darunavir as monotherapy or as triple ART. Neurocognitive impairment was defined as per the 2007 consensus of the American Association of Neurology. The association between neurocognitive impairment and protease inhibitor monotherapy, adjusted by significant confounders, was analysed. Results Of the 191 included patients - triple therapy: 96, 1–2 years of monotherapy: 40 and >2 years of monotherapy: 55 - proportions (95% CI) with neurocognitive impairment were: overall, 27.2% (20.9–33.6); triple therapy, 31.6% (22.1–41.0); short-term monotherapy, 25.0% (11.3–38.7); long-term monotherapy: 21.4% (10.5–32.3); p = 0.38. In all groups, neurocognitive impairment was mildly symptomatic or asymptomatic by self-report. There were not significant differences in Global Deficit Score by group. In the regression model confounding variables for neurocognitive impairment were years on ART, ethnicity, years of education, transmission category and the HOMA index. Adjusted by these variables the Odds Ratio (95% CI) for neurocognitive impairment of patients receiving short-term monotherapy was 0.85 (0.29–2.50) and for long-term monotherapy 0.40 (0.14–1.15). Conclusions Compared to triple drug antiretroviral therapy, monotherapy with lopinavir/ritonavir or darunavir/ritonavir in patients with adequate plasma suppression was not associated with a higher rate of asymptomatic neurocognitive impairment than triple drug ART.

Protease inhibitor (pharmacology)

Neurocognitive

Pharmacotherapy

10.1371/journal.pone.0069493

Cite

Citations (25)

[Cystosonography with echoenhancer. A new imaging technique for the diagnosis of vesicoureteral reflux].

PubMed (2000)

Berrocal Frutos T Francisco Gayá Nieves Gómez León Jaureguízar Monereo E

To analyze the utility of contrast enhanced ultrasonography of the bladder and kidneys (cystosonography) for the diagnosis of vesicoureteral reflux (VUR) by comparing the results of this new imaging modality with those of micturating cystourethrography (MCU).A total of 169 patients (293 kidney units) aged between 3 days and 18 years were sonographically evaluated for the presence of VUR after filling the bladder with saline and a galactose and palmitic acid suspension (Levograf) as an echoenhancing agent. Ultrasonographic images were obtained during bladder filling and micturation. This procedure was always followed by MCU during the same diagnostic session.In 50 kidney units both cystosonography and MUR detected VUR during bladder filling. In 22 units, only cystosonography detected passive reflux during bladder filling and in 3 only MCU did so. In 56 units, both methods detected active VUR during micturation. In 17 units, only cystosonography detected active reflux during micturation, the results of MCU being normal, and in 5, only MCU detected active reflux. Overall, of the 293 kidney units, VUR was not detected by either of the imaging modalities in 204(69.6%) and was detected by both methods, irrespective of whether it was active or passive, in 63(21.5%). In 19 units, VUR (active or passive) was observed only by cystosonography and in 7 only by MCU. When MCU was used as the reference method, cystosonography had a sensitivity of 90.5% and a specificity of 91.4%.Contrastenhanced cystosonography is a reliable modality, with sufficient sensitivity and specificity in the diagnosis of VUR and does not expose patients to ionizing radiation.

Urination

Source

Cite

Citations (4)

Lopinavir/Ritonavir as Single-Drug Therapy for Maintenance of HIV-1 Viral Suppression

JAIDS Journal of Acquired Immune Deficiency Syndromes (2005)

José Ramón Arribas Federico Pulido Rafaël Delgado Alicia Lorenzo Pilar Miralles

This study evaluated maintenance with lopinavir/ritonavir monotherapy vs. continuing lopinavir/ritonavir and 2 nucleosides in HIV-infected patients with suppressed HIV replication.Randomized, controlled, open-label, multicenter, pilot clinical trial.Adult patients were eligible if they had no history of virologic failure while receiving a protease inhibitor, were receiving 2 nucleosides + lopinavir/ritonavir (400/100 mg b.i.d.) for >1 month and had maintained serum HIV RNA <50 copies/mL for >6 months prior to enrollment.Forty-two patients were randomly assigned 1:1 to continue or stop the nucleosides. At baseline there were no significant differences between groups in median CD4 cells/muL (baseline or nadir), pre-HAART (highly active antiretroviral therapy) HIV log10 viremia, or time with HIV RNA <50 copies/mL prior to enrollment. After 48 weeks of follow-up, percentage of patients remaining at <50 HIV RNA copies/mL (intention to treat, M = F) was 81% for the monotherapy group (95% CI: 64% to 98%) vs. 95% for the triple-therapy group (95% CI: 86% to 100%); P = 0.34. Patients in whom monotherapy failed had significantly worse adherence than patients who remained virally suppressed on monotherapy. Monotherapy failures did not show primary resistance mutations in the protease gene and were successfully reinduced with prerandomization nucleosides. Mean change in CD4 cells/microL: +70 (monotherapy) and +8 (triple) (P = 0.27). Mean serum fasting lipids remained stable in both groups. No serious adverse events were observed.Most of the patients maintained with lopinavir/ritonavir monotherapy remain with undetectable viral load after 48 weeks. Failures of lopinavir/ritonavir monotherapy were not associated with the development of primary resistance mutations in the protease gene and could be successfully reinduced adding back prior nucleosides.

Lopinavir

Ritonavir

Lopinavir/ritonavir

Viremia

Protease inhibitor (pharmacology)

10.1097/01.qai.0000180077.59159.f4

Cite

Citations (152)

Neuroanatomic-Based Detection Algorithm for Automatic Labeling of Brain Structures in Brain Injury

IFMBE proceedings (2013)

Miguel A. Cabra de Luna Francisco Gayá Alberto García‐Molina Leo M. González Cesar A. Cáceres

Neurorehabilitation